Clinical effect of shenbing mistura combined with glucocorticoid on recurrent nephrotic syndrome in children and levels of interleukin-6 and tumor necrosis factor-alpha in blood and urine.
- Author:
Guo-hau HU
1
;
Xi-qiang DANG
;
Jing-he WANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Female; Follow-Up Studies; Glucocorticoids; therapeutic use; Humans; Interleukin-6; analysis; blood; urine; Male; Nephrotic Syndrome; drug therapy; pathology; Phytotherapy; Prednisone; therapeutic use; Recurrence; Treatment Outcome; Tumor Necrosis Factor-alpha; analysis; blood; urine
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(10):892-895
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of Shenbing Mistura (SM) combined with glucocorticoid on recurrent nephrotic syndrome (RNS) in children and levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in blood and urine.
METHODSThe treatment group was treated with SM plus glucocorticoid, the control group with glucocorticoid alone, and a healthy control group was adopted, 30 cases in each group. The clinical effect and recurrence rate were observed, and levels of IL-6 and TNF-alpha in blood and urine were determined before treatment and at the 4th, 8th, 12th week after treatment.
RESULTSSignificant difference of IL-6 and TNF-alpha levels in blood and urine was found in either the pre- and post- treatment auto-control of both the treatment group and control group, or in the inter-group comparison of them (P < 0.01); clinical effect also showed remarkable difference between the two groups (P < 0.01). Furthermore, the recurrence rate of the treatment group was lower than that of the control group showed by a 18-month follow-up (P < 0.01).
CONCLUSIONSM combined with glucocorticoid could significantly reduce the recurrence rate and elevate the clinical effect in children with RNS, it could also lower the levels of IL-6 and TNF-alpha in patients' blood and urine.
